R. Benza, Pittsburgh, PA, United States of America
Allegheny General HospitalPoster Author Of 2 e-Posters
Oral
PH - Pulmonary Arterial Hypertension
365 - Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function
Presentation Number
365
Co-Authors
- R. Benza, Pittsburgh, PA, United States of America
- D. Busse, Essen, Germany
- M. Chang, Berlin, Germany
- P. Colorado, Barcelona, Spain
- P. Corris, Newcastle, United Kingdom
- M. Hoeper, Hannover, Germany
- J. Klinger, Providence, RI, United States of America
- D. Langleben, Montreal, QC, Canada
- C. Meier, Berlin, Germany
- R. Naeije, Brussels, Belgium
- M. Patarroyo-Aponte, Pittsburgh, PA, United States of America
- G. Simonneau, Le Kremlin–Bicêtre, France
- C. Vizza, Rome, Italy
- H. Wirtz, Leipzig, Germany
Oral
PH - Therapeutics and Pharmacology
502 - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis
Presentation Number
502
Co-Authors
- R. Benza, Pittsburgh, PA, United States of America
- H. Ghofrani, Giessen, Germany
- M. Gomberg-Maitland, Chicago, IL, United States of America
- P. Klassen, San Diego, CA, United States of America
- E. Parsley, San Diego, CA, United States of America
- O. Sitbon, Le Kremlin-Bicêtre, France
- F. Torres, Dallas, TX, United States of America
- J. Zhang, San Diego, CA, United States of America